Morgan Stanley Bicycle Therapeutics PLC Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 1,349,894 shares of BCYC stock, worth $27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,349,894

Previous 1,231,573 9.61%

Holding current value

$27 Million

Previous $24.9 Million 22.82%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.58 - $27.24 $2.32 Million - $3.22 Million	118,321 Added 9.61%	1,349,894 $30.6 Million
Q2 2024 Oct 17, 2024	SELL	$20.02 - $24.69 $5.71 Million - $7.04 Million	-285,142 Reduced 18.8%	1,231,573 $24.9 Million
Q2 2024 Aug 14, 2024	SELL	$20.02 - $24.69 $5.71 Million - $7.04 Million	-285,142 Reduced 18.8%	1,231,573 $24.9 Million
Q1 2024 Oct 17, 2024	BUY	$16.75 - $26.1 $4.78 Million - $7.44 Million	285,142 Added 23.15%	1,516,715 $37.8 Million
Q1 2024 Aug 16, 2024	BUY	$16.75 - $26.1 $8.17 Million - $12.7 Million	487,490 Added 47.36%	1,516,715 $37.8 Million
Q1 2024 May 15, 2024	BUY	$16.75 - $26.1 $8.17 Million - $12.7 Million	487,490 Added 47.36%	1,516,715 $37.8 Million
Q4 2023 Aug 16, 2024	SELL	$13.29 - $22.2 $2.69 Million - $4.49 Million	-202,348 Reduced 16.43%	1,029,225 $18.6 Million
Q4 2023 Feb 13, 2024	SELL	$13.29 - $22.2 $7.87 Million - $13.2 Million	-592,524 Reduced 36.54%	1,029,225 $18.6 Million
Q3 2023 Nov 15, 2023	BUY	$19.9 - $26.25 $3.63 Million - $4.78 Million	182,182 Added 12.66%	1,621,749 $32.6 Million
Q2 2023 Aug 14, 2023	SELL	$18.95 - $28.67 $1.29 Million - $1.95 Million	-68,182 Reduced 4.52%	1,439,567 $36.7 Million
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $15.7 Million - $24.7 Million	786,190 Added 108.96%	1,507,749 $32.1 Million
Q4 2022 Feb 14, 2023	SELL	$20.37 - $32.9 $2.82 Million - $4.55 Million	-138,292 Reduced 16.08%	721,559 $21.4 Million
Q3 2022 Nov 14, 2022	BUY	$17.49 - $28.44 $675,936 - $1.1 Million	38,647 Added 4.71%	859,851 $20 Million
Q2 2022 Oct 27, 2022	BUY	$12.95 - $46.99 $9.5 Million - $34.5 Million	733,287 Added 834.07%	821,204 $13.8 Million
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $9.5 Million - $34.5 Million	733,287 Added 834.07%	821,204 $13.8 Million
Q1 2022 Oct 27, 2022	SELL	$40.12 - $59.5 $29.4 Million - $43.6 Million	-733,287 Reduced 89.29%	87,917 $3.86 Million
Q1 2022 May 13, 2022	SELL	$40.12 - $59.5 $2.49 Million - $3.69 Million	-62,095 Reduced 41.39%	87,917 $3.86 Million
Q4 2021 Feb 14, 2022	BUY	$41.7 - $61.14 $225,138 - $330,094	5,399 Added 3.73%	150,012 $9.13 Million
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $4.04 Million - $6.4 Million	144,613 New	144,613 $6.02 Million

Others Institutions Holding BCYC

# of Institutions

112

Shares Held

41.2M

Call Options Held

39.6K

Put Options Held

24.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $594M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account